This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

JNJ-56021927

Johnson & Johnson

Drug Names(s): ARN-509, JNJ56021927, JNJ-927

Description: JNJ-56021927 is an androgen receptor antagonist that inhibits nuclear translocation and DNA binding of the receptor, thereby modulating expression of genes that drive prostate cancer growth.

Deal Structure: Aragon and Johnson & Johnson
In June 2013, Aragon Pharmaceuticals announced a definitive agreement with Johnson & Johnson whereby Aragon will be acquired for $650 million in cash up front along with $350 million in contingent development milestone payments that could bring the total transaction value to $1 billion.

In August 2013, Johnson & Johnson announced it has successfully completed its acquisition of Aragon Pharmaceuticals.


JNJ-56021927 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug